Free Online Seminar: Fighting pancreatic cancer: current treatments, pipeline landscape, and PanCAN’s drug development projects
Date/Time: Dec. 7, 2021; 11:30AM – 13:30 (Pacific)
Details & Registration: https://www.pbss.org/aspx/eventInfo.aspx?eID=745
About the Topic: Drug development in metastatic pancreatic ductal adenocarcinoma (PDAC) has been disappointing with a 5 year survival rate of only 10% despite considerable effort.  Precision Promise is a transformative, adaptive registration clinical trial platform that attempts to correct this by continuously and rapidly evaluating novel therapeutic options while nurturing enhanced cooperation among groups representing patient advocacy, pharmaceuticals, translational/clinical academia, and the FDA. This patient-centric study represents a fundamental shift that can substantially accelerate drug development for PDAC . PanCAN is also leading translational research by facilitating genetic testing of patients with pancreatic cancer (“Know Your Tumor” program), and has recently launched an Early Detection Initiative (EDI) in patients with recent onset diabetes.

About the Speakers: As Chief Medical Officer for the Pancreatic Cancer Action Network, Anne-Marie Duliege, MD, is responsible for the strategic direction and operational oversight for the organization’s clinical initiatives, including PanCAN’s Precision Promise℠ clinical trial.